Please login to the form below

Not currently logged in

FDA grants Tocagen’s glioblastoma drug orphan status

Puts the brain cancer gene therapy in-line for development incentives

San-Diego based biopharmaceutical company Tocagen has secured orphan drug status for its investigational gene therapy treatment for glioblastoma.

It follows hard on the heels of the combination treatment Toca 511 & Toca FC winning fast track designation just last month assisting the company in its quest to further advance the drug's development.

Glioblastoma is the most common type of brain cancer, and most aggressive, with more than 10,000 new cases every year in the United States. However once diagnosed, patients have a five-year survival rate of less than 5%.

Harry Gruber, CEO of Tocagen, said: “There's an extraordinary need for new treatment options for patients with this devastating disease.

“We believe the FDA's granting of both orphan drug and fast track designations to Toca 511 & Toca FC will enable us to more efficiently advance our programme, which we hope will ultimately offer physicians and patients a new option in the fight against brain cancer.”

Both components of the combination treatment are designed to programme cancer cells to convert prodrug 5-FC into the FDA-approved anticancer drug, 5-flurorouracil (5-FU), which kills tumour cells and additionally significantly boosts immune responses.

Toca 511 is an injectable retroviral replicator vector that delivers a gene, responsible for the enzyme cytosine deaminase, to the tumour.

This is followed with oral doses of Toca FC which is converted within infected cancer cells into 5-FU, killing cancer cells while preserving healthy host cells.

The treatment will enter phase II and III trials later this year and so far interim results have shown median survival rates of 13.8 months compared with historical benchmarks of around 7 months.

This programme will be supported by companion diagnostic tests that Tocagen is working on in partnership with Siemens Healthcare Diagnostics under an agreement signed last year.

Article by
Nikhil Patel

26th August 2015

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
Senior Analytics Specialist joins Research Partnership...